STOCK TITAN

APGE (NASDAQ: APGE) holder plans sale of 1.75M common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A holder of Apogee Therapeutics (symbol APGE) common stock filed a Form 144 notice to potentially sell 1,750,000 shares through broker Jefferies LLC on or about 01/22/2026 on the NASDAQ. The filing lists an aggregate market value for the planned sale of $133,525,000.00, based on current market prices, compared with 54,833,587 shares of the class outstanding. The shares were originally purchased in the initial public offering on 07/13/2023 from the issuer for cash, with payment dated 07/18/2023.

By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, and acknowledges that intentional misstatements or omissions would be a federal criminal violation.

Positive

  • None.

Negative

  • None.

Insights

Large Form 144 sale notice, but informational rather than thesis-changing.

The Form 144 indicates an intent to sell 1,750,000 common shares, with an aggregate market value of $133,525,000.00, versus 54,833,587 shares of that class outstanding. This is a sizable potential sale but remains a notice of planned disposition rather than a completed transaction, and it follows an initial purchase in the IPO on 07/13/2023 paid in cash on 07/18/2023.

The filing names Jefferies LLC as broker and the NASDAQ as the exchange, suggesting ordinary market transactions rather than a special structured deal. The signer represents they do not know of undisclosed material adverse information about the issuer’s operations. Actual market impact, if any, would depend on execution of the sales and prevailing trading liquidity.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does APGE's Form 144 filing disclose?

It discloses that a holder of APGE common stock has filed a notice of intent to sell 1,750,000 shares on the NASDAQ through Jefferies LLC, with an indicated aggregate market value of $133,525,000.00.

How large is the planned APGE share sale compared to shares outstanding?

The Form 144 lists 1,750,000 common shares to be sold and shows 54,833,587 shares of that class outstanding at the time, providing context for the size of the potential sale.

When were the APGE shares in this Form 144 originally acquired?

The filing states the common shares were purchased in the initial public offering on 07/13/2023 from the issuer, with cash payment dated 07/18/2023.

What is the approximate date of sale in APGE's Form 144 notice?

The notice specifies an approximate sale date of 01/22/2026 for the 1,750,000 common shares to be sold on the NASDAQ.

Which broker is handling the potential APGE Form 144 sale?

The Form 144 identifies Jefferies LLC, located at 520 Madison Ave, New York, NY 10022, as the broker for the planned sale of APGE common shares.

What representation does the seller make in the APGE Form 144?

By signing, the seller represents they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, and acknowledges that intentional misstatements or omissions are federal criminal violations.

Apogee Therapeutics Inc

NASDAQ:APGE

APGE Rankings

APGE Latest News

APGE Latest SEC Filings

APGE Stock Data

5.60B
50.10M
7.59%
132.45%
15.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WALTHAM